Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A1 A*02:01 TCR-T
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A1 A*02:01 TCR-T is an autologous T-cell receptor (TCR) engineered T-cell therapy developed by Anocca. The therapy utilizes T cells that have been genetically modified to express a TCR specifically designed to recognize the Melanoma-associated antigen 1 (MAGE-A1) peptide when presented by the HLA-A*02:01 major histocompatibility complex. MAGE-A1 is a cancer-testis antigen that is highly expressed in various malignancies, including melanoma, breast cancer, and lung cancer, but has restricted expression in normal tissues, making it a suitable target for immunotherapy. By engineering a patient's own T cells to target this specific antigen-HLA complex, the therapy aims to induce a potent and selective cytotoxic immune response against tumor cells. It is currently being investigated in Phase 1 clinical trials for the treatment of MAGE-A1-positive solid tumors.
- Other names
- Anocca MAGE-A1 TCR-TMAGE-A1 HLA-A*02:01 TCR-T cell therapy
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MAGE-A1 A*02:01 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A1 A*02:01 TCR-T.